[The clinico-immunological evaluation of the ribomunyl treatment of chronic bronchitis patients].
The paper reports the results of ribomunil trial in chronic bronchitis (CB) patients who suffered from frequent exacerbations. The drug was found to act primarily on a phagocytic component of the immunity and local immunity of the respiratory mucosa. Because of its vaccine-like effect, ribomunil administration is most beneficial in CB remission. Ribomunil treatment results in reduction of the number and duration of CB exacerbations, of the scope of antibacterial therapy.
Borisova
A M
AM
Khoroshilova
N V
NV
Pinegin
B V
BV
Eremina
O F
OF
Simonova
A V
AV
Kulakov
A V
AV
Golubeva
N M
NM
Dykhanov
I I
II
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000917:Antibody Formation / Q000187:drug effects; D000942:Antigens, Bacterial / Q000009:adverse effects / Q000627:therapeutic use*; D001991:Bronchitis / Q000188:drug therapy* / Q000276:immunology; D002908:Chronic Disease; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D008875:Middle Aged; D010919:Placebos
D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial; D010919:Placebos; C034206:Ribomunyl
Kliniko-immunologicheskaia otsenka lecheniia ribomunilom bol'nykh khronicheskim bronkhitom.